1-5 of 5
Erwin Van Puijenbroek
Close
Sort by
Journal Articles

A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys

Minh Diem Vu, PhD, Samuel Moser, MSc, Camille Delon, MSc, Melanie Latzko, MSc, Reto Gianotti, MSc, Remo Lüoend, BSc, Chloé Friang, MSc, Ramona Murr, MSc, Lydia Jasmin Duerner, PhD, Tina Weinzierl, PhD, Tanja Fauti, PhD, Marina Bacac, PhD, Oliver Ast, PhD, Anne Freimoser-Grundschober, PhD, Tea Rodriguez Diaz, MSc, Jörg Zielonka, PhD, Erwin van Puijenbroek, PhD, Ralf Hosse, PhD, Peter Bruenker, PhD, Ekkehard Mössner, PhD, Christian Klein, PhD, Pablo Umaña, PhD, Klaus Strein, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2998.
https://doi.org/10.1182/blood.V126.23.2998.2998
Published: 2015
Journal Articles

Novel Tumor-Targeted, Engineered IL-2 Variant (IL2v)-Based Immunocytokines For Immunotherapy Of Cancer

Christian Klein, PhD, Inja Waldhauer, PhD, Valeria Nicolini, PhD, Claire Dunn, PhD, Anne Freimoser-Grundschober, PhD, Gerrits Danny, PhD, Otto Boerman, PhD, Tapan Nayak, PhD, Sylvia Herter, PhD, Erwin Van Puijenbroek, Oliver Ast, PhD, Thomas Hofer, PhD, Ralf Hosse, Sabine Lang, Sebastian Neumann, Hubert Kettenberger, Markus Neubauer, Ingo Gorr, Dietrich Tuerck, Stefan Evers, Christian Gerdes, Victor Levitsky, Marina Bacac, Ekkehard Moessner, Pablo Umana, PhD
Journal: Blood
Blood (2013) 122 (21): 2278.
https://doi.org/10.1182/blood.V122.21.2278.2278
Published: 2013
Journal Articles

Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101 vs . the Type I CD20 Antibodies Rituximab and Ofatumumab

Sylvia Herter, Inja Waldhauer, Tina Otz, Frank Herting, Sabine Lang, Valeria Nicolini, Michaela Römmele, Thomas Friess, Erwin Van Puijenbroek, Marina Bacac, K. Michael Weidner, PhD, Christian Gerdes, Pablo Umana, PhD, Christian Klein, PhD
Journal: Blood
Blood (2010) 116 (21): 3925.
https://doi.org/10.1182/blood.V116.21.3925.3925
Published: 2010
Journal Articles

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Ekkehard Mössner, Peter Brünker, Samuel Moser, Ursula Püntener, Carla Schmidt, Sylvia Herter, Roger Grau, Christian Gerdes, Adam Nopora, Erwin van Puijenbroek, Claudia Ferrara, Peter Sondermann, Christiane Jäger, Pamela Strein, Georg Fertig, Thomas Friess, Christine Schüll, Sabine Bauer, Joseph Dal Porto, Christopher Del Nagro, Karim Dabbagh, Martin J. S. Dyer, Sibrand Poppema, Christian Klein, Pablo Umaña
Journal: Blood
Blood (2010) 115 (22): 4393–4402.
https://doi.org/10.1182/blood-2009-06-225979
Published: 2010
Journal Articles

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Mediates Superior Efficacy in a Variety of NHL Xenograft Models in Comparison to Rituximab.

Thomas Friess, PhD, Christian Gerdes, PhD, Adam Nopora, PhD, Monika Patre, PhD, Susanne Preiss, PhD, Erwin van Puijenbroek, Christine Schuell, PhD, Sabine Bauer, PhD, Pablo Umana, PhD, Christian Klein, PhD
Journal: Blood
Blood (2007) 110 (11): 2338.
https://doi.org/10.1182/blood.V110.11.2338.2338
Published: 2007